Latest News - West Pharmaceutical
Top Corporates Hub
West Pharmaceutical
Why Is Align Technology (ALGN) Up 9.4% Since Last Earnings Report?
29.08.2025 15:30
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
COO Q3 Earnings Beat, 2025 Sales Outlook Lowered, Stock Down
29.08.2025 13:47
Cooper Companies beats on Q3 earnings with 15% EPS growth, but revenue weakness and a trimmed 2025 outlook send shares tumbling.
Here's Why You Should Add CLOV Stock to Your Portfolio Now
29.08.2025 13:47
Clover's strong membership growth, rising revenues, and first-half EBITDA profitability highlight its tech-driven Medicare Advantage edge.
1 S&P 500 Stock on Our Watchlist and 2 Facing Challenges
29.08.2025 04:39
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
VEEV Q2 Earnings & Revenues Beat Estimates, Margin Rises, Stock Up
28.08.2025 14:24
Veeva Systems' second-quarter earnings and revenues beat estimates, margins expand and raised FY26 outlook lifts shares higher.
West to Participate in Upcoming Investor Conferences in September 2025
21.08.2025 10:00
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at multiple investor conferences in September. Here are the details of the presentations:
Nilesh Shah joins Illumina as Head of Region, AMEA
19.08.2025 06:14
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of Nilesh Shah as Head of Region, AMEA, effective immediately.
Encompass Health Q2 Earnings Beat Estimates, Stock Up 7.4%
11.08.2025 16:59
EHC posts strong Q2 with higher EPS, revenue growth, and a raised 2025 outlook, along with shares gaining 7.4%.
4 Dental Supplies Stocks Likely to Gain Amid Rising Tariff Risks
11.08.2025 12:28
Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.
The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call
31.07.2025 05:33
West Pharmaceutical Services delivered a quarter that outperformed Wall Street’s expectations, reflecting renewed strength in its core high-value product (HVP) components. Management attributed the results primarily to robust demand for GLP-1 elastomer products, ongoing conversions to HVP driven by regulatory upgrades, and the normalization of customer ordering patterns. CEO Eric Green highlighted that the company’s proprietary products segment saw particularly solid growth, with HVP components
West Pharmaceutical: Q2 Earnings Snapshot
25.07.2025 11:02
The Exton, Pennsylvania-based company said it had net income of $1.82 per share. Earnings, adjusted for restructuring costs and amortization costs, came to $1.84 per share. The results exceeded Wall Street expectations.
WST Q2 Deep Dive: High-Value Product Momentum Drives Guidance Increase
25.07.2025 05:34
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 9.2% year on year to $766.5 million. The company’s full-year revenue guidance of $3.05 billion at the midpoint came in 3.1% above analysts’ estimates. Its non-GAAP profit of $1.84 per share was 22% above analysts’ consensus estimates.
West Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look For
23.07.2025 03:08
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results this Thursday morning. Here’s what you need to know.
West Welcomes Robert McMahon as Incoming Chief Financial Officer
21.07.2025 10:00
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition.
Drug Development Inputs & Services Stocks Q1 Results: Benchmarking West Pharmaceutical Services (NYSE:WST)
16.07.2025 03:34
Let’s dig into the relative performance of West Pharmaceutical Services (NYSE:WST) and its peers as we unravel the now-completed Q1 drug development inputs & services earnings season.
West to Host Second-Quarter 2025 Conference Call
08.07.2025 06:01
EXTON, Pa., July 8, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. , a global leader in innovative solutions for injectable drug administration, today announced that it will release...
WST Shareholders Have the Right to Lead the West Pharmaceutical Services, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - WST
07.07.2025 02:24
LOS ANGELES, July 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against West Pharmaceutical Services, Inc. for violations of the federal securities laws. ...
Deadline Soon: West Pharmaceutical Services, Inc. (WST) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
02.07.2025 12:03
The Law Offices of Frank R. Cruz reminds investors of the upcoming July 7, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors...
Pomerantz Law Firm Reminds Investors with Losses on their Investment in West Pharmaceutical Services, Inc. of Class Action Lawsuit and Upcoming Deadlines - WST
02.07.2025 10:01
NEW YORK, July 2, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. . Such investors are advised to contact...